- Details
- Zachary Klaassen speaks with Pedro Barata about a publication examining transcription profiles in renal cell carcinoma. The discussion explores the evolution from DNA-based to RNA-based genomic analysis in RCC, focusing on their study of over 600 patients' gene expression signatures across different RCC subtypes. Dr. Barata emphasizes that non-clear cell RCC comprises biologically distinct cancers...
|
- Details
- Alicia Morgans speaks with Jonathan Rosenberg about two novel therapies presented at ESMO 2024. The discussion centers on BL-B01D1, a bispecific antibody-drug conjugate targeting EGFR and HER3 in advanced urothelial cancer, which shows promising early results with a 40% response rate in previously treated patients. The conversation also explores NKT2152, a HIF2a inhibitor for renal cell carcinoma,...
|
- Details
- Leslie Ballas interviews Chad Tang about the use of stereotactic body radiation therapy (SBRT) in metastatic renal cell carcinoma (RCC). Dr. Tang discusses two key approaches: treating oligometastatic disease (up to five metastatic sites) and oligoprogressive disease (one to three progressing sites). He presents data from recent studies showing SBRT's potential to delay the need for systemic thera...
|
- Details
- Sam Chang interviews Ignacio Duran about the highlights of ESMO 2024 in non-prostate genitourinary oncology. Dr. Duran discusses key findings in kidney and bladder cancer. For kidney cancer, he highlights studies challenging the sequencing of checkpoint inhibitors and new treatment options for non-clear cell carcinoma. In bladder cancer, Dr. Duran reviews three studies that could impact clinical p...
|
- Details
- Alicia Morgans interviews David Braun about novel serum glycoproteomic biomarkers in the CheckMate 9ER study for kidney cancer. Dr. Braun discusses the exploratory post-hoc analysis using the InterVenn GlycoVision Glycoproteomics platform to investigate potential prognostic and predictive biomarkers. He highlights findings that higher levels of glycosylation are associated with worse outcomes, reg...
|
- Details
- Zachary Klaassen interviews Laurence Albiges about the CaboPoint Phase II Trial. Dr. Albiges discusses the evolving landscape of second-line treatment for clear cell renal cell carcinoma (RCC) after first-line immunotherapy combinations. The CaboPoint study evaluates cabozantinib as a pure second-line treatment in patients who have failed either nivolumab-ipilimumab or an IO-TKI strategy. Results...
|
- Details
- Chiara Ciccarese discusses the TACITO-II trial results, evaluating fecal microbiota transplantation (FMT) in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma. The phase II randomized study shows promising results, with FMT increasing the one-year progression-free survival rate from 35% to 66.7%. Dr. Ciccarese highlights the trial's novelty in demonstrating the tra...
|
- Details
- Eric Jonasch discusses data on NKT2152, a novel HIF-2 alpha inhibitor for clear cell renal cell carcinoma. The phase 1/2 study shows promising results in heavily pre-treated patients, with objective response rates around 25% and median progression-free survival of 7.4 months. Dr. Jonasch highlights the drug's efficacy across risk groups and its favorable safety profile, with anemia as the most com...
|
- Details
- Mark Ball and Jessica Hsueh discuss a study on using GPT-4 for data extraction from renal surgery operative notes. The research compares GPT-4's performance to human-curated data across five variables: laterality, surgery type, approach, estimated blood loss, and ischemia time. Results show high accuracy for categorical variables but lower accuracy for continuous variables and heterogeneously writ...
|
- Details
- John Babich discusses the potential of radiopharmaceuticals in cancer treatment. He emphasizes the importance of targeting and retention in tumor tissues, explaining the concept of therapeutic index and the company's "radioligand first, isotope second" approach. Dr. Babich highlights their work on FAP (fibroblast activation protein) and their Trillium technology, which aims to optimize drug delive...
|
